VIEWPOINT

Drug eluting stents: maximising benefit and minimising cost

J Gunn¹, A C Morton¹, C Wales¹, C M H Newman¹, D C Crossman¹, D C Cumberland²

¹ Cardiovascular Research Group, Division of Clinical Sciences (Northern General Hospital), University of Sheffield, Sheffield, UK
² Ampang Puteri Specialist Hospital, Jalang Memanda, Mukin Ampang, Selangor, Malaysia

Correspondence to:
Dr Julian Gunn, Cardiovascular Research Group, Division of Clinical Sciences (Northern General Hospital), University of Sheffield, Clinical Sciences Building, Northern General Hospital, Sheffield, S5 7AU, UK;
J.Gunn{at}Sheffield.ac.uk

A policy of selective implantation of drug eluting stents, in a minority of lesions most likely to benefit, seems to be a rational way to employ this new and currently costly technology

Keywords: drug eluting stents; sirolimus; percutaneous coronary intervention; restenosis

Abbreviations: CABG, coronary artery bypass grafting; IVUS, intravascular ultrasound; MLD, minimum lumen diameter; PCI, percutaneous coronary intervention; RAVEL, randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization; SIRIUS, US multicenter, randomized, double-blind study of the sirolimus-eluting stent in de novo coronary lesions; TLR, target lesion revascularisation; TVF, target vessel failure

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Siotia, A K, Morton, A C, Mofidi, S, Wales, C, Newman, C, Gunn, J (2007). Targeting drug-eluting stents to lesions at high risk of restenosis: a flawed approach?. Heart 93: 251-252 [Full Text]  
• Eisenberg, M. J. (2006). Drug-Eluting Stents: The Price Is Not Right. Circulation 114: 1745-1754 [Full Text]  
• Waksman, R, Leitch, I M, Roessler, J, Yazdi, H, Seabron, R, Tio, F, Scott, R W, Grove, R I, Rychnovsky, S, Robinson, B, Pakala, R, Cheneau, E (2006). Intracoronary photodynamic therapy reduces neointimal growth without suppressing re-endothelialisation in a porcine model. Heart 92: 1138-1144 [Abstract] [Full Text]  
• Murphy, G. J., Bryan, A. J., Angelini, G. D. (2004). Hybrid Coronary Revascularization in the Era of Drug-Eluting Stents. Ann. Thorac. Surg. 78: 1861-1867 [Abstract] [Full Text]  
• Hill, R. A., Dundar, Y., Bakhai, A., Dickson, R., Walley, T. (2004). Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 25: 902-919 [Abstract] [Full Text]  

eLetters:

Read all eLetters

Brutal analysis suggests that current drug-elution costs are never financially justifiable

Darrel P Francis

Online, 5 Feb 2003 [Full text]

Drug-eluting stents: maximising benefit and minimising cost

Julian Gunn, et al.

Online, 17 Feb 2003 [Full text]

National Institute of Clinical Excellence

J Gunn, et al.

Online, 6 Oct 2003 [Full text]